Your new experience awaits. Try the new design now and help us make it even better

CASE REPORT article

Front. Oncol.

Sec. Surgical Oncology

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1572068

Intracranial Neuroendocrine Carcinoma with Coexisting Pituitary Adenoma: A Case Report and Comprehensive Literature Review

Provisionally accepted
Wei  KangWei Kang1Xitong  LiuXitong Liu2Anle  DuanAnle Duan3Beiyan  TangBeiyan Tang4Qiang  DongQiang Dong1Xianjun  ZhaoXianjun Zhao1Lei  DuanLei Duan1Yawen  PanYawen Pan1,5*
  • 1Department of Neurosurgery, Lanzhou University Second Hospital, Lanzhou, Gansu Province, China
  • 2Lanzhou University Second Hospital, Lanzhou, Gansu Province, China
  • 3Third People's Hospital of Gansu Province, Lanzhou, Gansu Province, China
  • 4Lanzhou University, Lanzhou, China
  • 5Key Laboratory of Neurology of Gansu Province, Lanzhou, Gansu Province, China

The final, formatted version of the article will be published soon.

Neuroendocrine carcinomas (NECs) originating from intracranial sites are exceedingly rare. Here, we present the case of a 29-year-old female with intracranial NEC coexisting with a pituitary adenoma (PA). The patient's symptoms included intermittent headaches, visual impairment, and endocrine abnormalities. Imaging studies revealed a large lobulated mass in the left frontal lobe and a mass lesion in the sellar region. Laboratory investigations indicated elevated levels of prolactin (PRL) and growth hormone (GH). Surgical resection of the frontal lobe tumor was performed initially, followed by neuroendoscopic transsphenoidal resection of the sellar lesion. The case underscores the diagnostic complexity of intracranial NEC due to its nonspecific clinical and radiological manifestations. Surgery remains the primary treatment modality, with adjunctive radiotherapy and chemotherapy. Further research is essential to enhance diagnostic accuracy and refine treatment strategies for intracranial NEC.

Keywords: neuroendocrine carcinoma, Intracranial tumor, pituitary adenoma, Clinical manifestation, Pathology, Treatment

Received: 11 Feb 2025; Accepted: 18 Aug 2025.

Copyright: © 2025 Kang, Liu, Duan, Tang, Dong, Zhao, Duan and Pan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Yawen Pan, Key Laboratory of Neurology of Gansu Province, Lanzhou, Gansu Province, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.